Protection to homologous and heterologous challenge in pigs immunized with vaccine against foot-and-mouth disease type O caused an epidemic in East Asia during 2010/2011

Park, Jeong-Nam; Lee, Seo-Yong; Chu, Jiaqi; Lee, Yeo-Joo; Kim, Rae-Hyung; Lee, Kwang‐Nyeong; Kim, Su-Mi; Tark, Dongseob; Kim, Byounghan

doi:10.1016/j.vaccine.2014.01.067

Cited by 32 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination against FMD during an outbreak is an additional measure that can be used to successfully control an outbreak in non-endemic countries. Although vaccines can offer clinical protection against the disease, they are less effective in preventing infection, virus excretion and sometimes, establishment of persistent infection (Cox et al, 2006;Golde et al, 2005;Muthukrishnan et al, 2012;Park et al, 2014;Stenfeldt et al, 2016a). However, several studies have shown that vaccination results in reduction of virus excretion and clinical signs when compared to unvaccinated animals (Stenfeldt et al, 2016a;Barnett et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

et al. 2017

View full text Add to dashboard Cite

Potency tests for commercial oil-adjuvanted foot-and-mouth disease (FMD) vaccines are usually carried out in cattle, using a full dose (2 ml) of vaccine and homologous virus challenge. However, in sheep the recommended vaccine dose is half of the cattle dose (1 ml) and most vaccines have not been potency tested for this species, especially with heterologous viruses. To determine the efficacy of a high potency (>6PD) FMD virus (FMDV) O1Manisa vaccine in sheep, we carried out a study using a heterologous FMDV (FMDV O/SKR/2010 - Mya-98 strain) challenge. Groups of seven animals each were vaccinated with 2×, 1×, 1/2× or 1/4× dose (2 ml, 1 ml, 0.5 ml or 0.25 ml respectively) and challenged at 7 days post vaccination (dpv). Only 3 of the 7 sheep in the group vaccinated with 2 ml were protected. With 2 additional groups, receiving double or single doses and challenged at 14 dpv, 4 of 7 sheep were protected in each group. None of the sheep had measurable neutralising antibodies against the vaccine or challenge virus at 7 dpv. However, all vaccinated animals challenged at 14 dpv had a homologous neutralising response against FMDV O1 Manisa on the day of challenge and all but one animal also had a heterologous response to FMDV O/SKR/2010. Infectious FMDV and viral RNA could be found in nasal swabs between 1 and 6 days post challenge (dpc) in most vaccinated sheep, but those vaccinated with higher doses or challenged at 14 dpv showed significant decreases in the level of FMDV detection. Intermittent virus shedding was noticed between 1 and 35 dpc in all vaccinated groups, but persistent infection could be demonstrated only in 4 sheep (20%). This study showed that at the recommended dose, a high potency (>6 PD) FMDV O1Manisa vaccine does not protect sheep against a heterologous challenge at 7 dpv. However, partial protection was observed when a double dose was used at 7 dpv or when double or single dose vaccinated sheep were challenged at 14 dpv.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In response to an FMD epidemic in Southeast Asia where there was only a moderate match between field and O Manisa vaccine strains ( r 1 around 0.3), Park et al (35) performed homologous and heterologous challenge studies to evaluate a new vaccine seed strain (O/Andon/SKR/2010). Groups of five, FMD antibody-free, 3-month-old pigs received one of three different antigen payloads (7.5, 10, and 15 μg) in an oil-adjuvanted vaccine and were intradermally challenged 30 dpv with the homologous O/Andon/SKR/2010 strain.…”

Section: Vaccine Potency and Protectionmentioning

confidence: 99%

“…Guo et al (68) reported that a CpG-enriched plasmid enhanced the efficacy of a conventional FMD killed vaccine. Park et al (35, 69) vaccinated groups of five pigs with a conventional FMD vaccine antigen plus either the oil adjuvant used in the Republic of Korea or with novel adjuvants (Carbigen, Emulsigen-D and ISA 201). In terms of immune response and post-challenge protection, the novel antigens were at least as good.…”

Section: Novel Approaches To Vaccines and Vaccinationmentioning

confidence: 99%

Challenges of Generating and Maintaining Protective Vaccine-Induced Immune Responses for Foot-and-Mouth Disease Virus in Pigs

et al. 2016

View full text Add to dashboard Cite

Vaccination can play a central role in the control of outbreaks of foot-and-mouth disease (FMD) by reducing both the impact of clinical disease and the extent of virus transmission between susceptible animals. Recent incursions of exotic FMD virus lineages into several East Asian countries have highlighted the difficulties of generating and maintaining an adequate immune response in vaccinated pigs. Factors that impact vaccine performance include (i) the potency, antigenic payload, and formulation of a vaccine; (ii) the antigenic match between the vaccine and the heterologous circulating field strain; and (iii) the regime (timing, frequency, and herd-level coverage) used to administer the vaccine. This review collates data from studies that have evaluated the performance of foot-and-mouth disease virus vaccines at the individual and population level in pigs and identifies research priorities that could provide new insights to improve vaccination in the future.

show abstract

“…It is caused by FMD virus, a picornavirus, the prototypical member of the genus Aphthovirus. The South East Asia (SEA) topotype is the most prevalent in Asian countries, which commonly affected cattle and swine during the FMD outbreak in the East Asian region during 2010 and 2011 (Park et al, 2014). During this outbreak, direct economic losses were estimated to be 3 billion US$ (Sakamoto, 2012;Park et al, 2013;Saeed et al, 2015) due to the culling of 3.48 million susceptible animals.…”

Section: Introductionmentioning

confidence: 99%

“…During this outbreak, direct economic losses were estimated to be 3 billion US$ (Sakamoto, 2012;Park et al, 2013;Saeed et al, 2015) due to the culling of 3.48 million susceptible animals. Recently, an inactivated oil-based vaccine has been developed using viruses of the O-SEA-topotype isolated in Korea and has demonstrated that vaccinated pigs (at least 7.5 µg antigen/pig) are effectively protected against homologous or heterologous viral challenge (Park et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Serum concentration of acute phase proteins and cytokines in vaccinated pigs challenged with foot-and-mouth disease virus serotype O

Lee

Lillehoj

et al. 2019

R. Bras. Zootec.

Self Cite

View full text Add to dashboard Cite

The present study aimed to investigate the kinetics of acute phase proteins and cytokines in the serum of immunized or naive pigs following infection with a field isolate of foot-and-mouth disease (FMD) virus. Five-month-old SPF pigs were intramuscularly immunized with or without the 146S antigen (7.5 μg per head) purified from FMD virus (O/Andong/SKR/2010) and were subsequently challenged 30 days post-vaccination (dpv) with FMD virus on each footpad. Serum samples were obtained at 28 dpv and on days 1, 3, and 5 post-infection (dpi). At 28 dpv, the serum concentrations of C-reactive protein and tumor necrosis factor alpha (TNF-α) were higher in the immunized pigs compared with the non-immunized control pigs. Upon challenge, the levels of all measured acute phase proteins (i.e., C-reactive protein, major acute phase protein, S-amyloid A, and haptoglobin) plateaued at 1 dpi in the immunized pigs whereas they gradually increased up to 5 dpi in the non-immunized control pigs. Levels of serum TNF-α remained higher in the immunized challenged pigs compared with the non-immunized challenged pigs. The serum concentration of interleukin (IL)-6 in the immunized challenged pigs was undetectable at all time points, but moderately increased upon challenge in the non-immunized challenged pigs. IL-1β was not detected in any of the pigs at any of the observed time points. Collectively, these findings show that the immunized pigs exhibit a rapid serum acute phase protein response following subsequent challenge with the field FMD virus compared with the non-immunized pigs.

show abstract

Protection to homologous and heterologous challenge in pigs immunized with vaccine against foot-and-mouth disease type O caused an epidemic in East Asia during 2010/2011

Cited by 32 publications

References 24 publications

Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

Challenges of Generating and Maintaining Protective Vaccine-Induced Immune Responses for Foot-and-Mouth Disease Virus in Pigs

Serum concentration of acute phase proteins and cytokines in vaccinated pigs challenged with foot-and-mouth disease virus serotype O

Contact Info

Product

Resources

About